Antiviral Strategies for Pandemic and Seasonal Influenza
Author Information
Author(s): Hedlund Maria, Larson Jeffrey L., Fang Fang
Primary Institution: NexBio, Inc.
Hypothesis
The review focuses on the effectiveness of antiviral drugs and drug candidates against influenza, particularly the host-targeting entry-blocker DAS181.
Conclusion
DAS181 shows broad-spectrum activity against various influenza strains, including those resistant to current antiviral treatments.
Supporting Evidence
- DAS181 has been shown to inhibit influenza and parainfluenza virus replication in various in vitro and ex vivo models.
- DAS181 is effective against seasonal influenza strains, including those resistant to neuraminidase inhibitors.
- Clinical studies indicate that DAS181 does not increase bacterial colonization in the respiratory tract.
Takeaway
This study looks at different medicines to fight the flu, especially a new one called DAS181 that helps stop the virus from getting into our cells.
Methodology
The review summarizes existing antiviral drugs and discusses new candidates in clinical development, focusing on their mechanisms and effectiveness.
Limitations
The review does not provide new experimental data but summarizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website